Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery

[1]  M. Hediger,et al.  Transporter-Mediated Drug Delivery , 2023, Molecules.

[2]  Dohyun Kim,et al.  Peptide permeation enhancers for improving oral bioavailability of macromolecules , 2022, Journal of Pharmaceutical Investigation.

[3]  Shiqing Ma,et al.  A drug delivery system constructed by a fusion peptide capturing exosomes targets to titanium implants accurately resulting the enhancement of osseointegration peri-implant , 2022, Biomaterials Research.

[4]  Yafeng Wu,et al.  Efficiently targeted therapy of glioblastoma xenograft via multifunctional biomimetic nanodrugs , 2022, Biomaterials Research.

[5]  Jianfei Xie,et al.  Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate , 2022, Biomaterials Research.

[6]  Y. Byun,et al.  Enhancement of the anticancer effect of atorvastatin-loaded nanoemulsions by improving oral absorption via multivalent intestinal transporter-targeting lipids , 2022, Drug delivery.

[7]  L. Blonde,et al.  A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes , 2022, Reviews in Endocrine and Metabolic Disorders.

[8]  Y. Byun,et al.  Enhanced oral absorption of teriparatide with therapeutic potential for management of osteoporosis. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Y. Bae,et al.  Bile Acid Conjugation on Solid Nanoparticles Enhances ASBT‐Mediated Endocytosis and Chylomicron Pathway but Weakens the Transcytosis by Inducing Transport Flow in a Cellular Negative Feedback Loop , 2022, Advanced science.

[10]  Y. Han Bae,et al.  Lipid raft-mediated and upregulated coordination pathways assist transport of glycocholic acid-modified nanoparticle in a human breast cancer cell line of SK-BR-3. , 2022, International journal of pharmaceutics.

[11]  Chun Gwon Park,et al.  Immune cell targeting nanoparticles: a review , 2021, Biomaterials Research.

[12]  J. Subramony,et al.  Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease , 2021, Scientific Reports.

[13]  Taekwang Keum,et al.  Recent progress in hydrophobic ion-pairing and lipid-based drug delivery systems for enhanced oral delivery of biopharmaceuticals , 2021, Journal of Pharmaceutical Investigation.

[14]  K. Na,et al.  ι-Carrageenan nanocomposites for enhanced stability and oral bioavailability of curcumin , 2021, Biomaterials Research.

[15]  Yuanjin Zhao,et al.  Magneto‐Responsive Microneedle Robots for Intestinal Macromolecule Delivery , 2021, Advanced materials.

[16]  Y. Choi,et al.  Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[17]  S. Ingwersen,et al.  Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials , 2021, Clinical Pharmacokinetics.

[18]  Jin Woo Park,et al.  Intestinal membrane transporter-mediated approaches to improve oral drug delivery , 2021, Journal of Pharmaceutical Investigation.

[19]  A. Igarashi,et al.  Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment , 2020, Advances in Therapy.

[20]  K. Boye,et al.  Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study , 2020, Diabetes, obesity & metabolism.

[21]  Y. Bae,et al.  Bile acid transporter-mediated oral drug delivery. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[22]  S. Heller,et al.  Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen , 2020, BMJ open diabetes research & care.

[23]  Dongyang Zhao,et al.  Intestinal OCTN2- and MCT1-targeted drug delivery to improve oral bioavailability , 2020, Asian journal of pharmaceutical sciences.

[24]  Robert Langer,et al.  A luminal unfolding microneedle injector for oral delivery of macromolecules , 2019, Nature Medicine.

[25]  G. Guichard,et al.  Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo , 2019, Nature Communications.

[26]  Robert Langer,et al.  An ingestible self-orienting system for oral delivery of macromolecules , 2019, Science.

[27]  David J Brayden,et al.  Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10) , 2019, Pharmaceutics.

[28]  J. Ahnfelt-Rønne,et al.  Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist , 2018, Science Translational Medicine.

[29]  P. Tyagi,et al.  Oral peptide delivery: Translational challenges due to physiological effects , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[30]  P. Cullen,et al.  To degrade or not to degrade: mechanisms and significance of endocytic recycling , 2018, Nature Reviews Molecular Cell Biology.

[31]  Søren L Pedersen,et al.  Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives. , 2018, ACS medicinal chemistry letters.

[32]  Yi Jin,et al.  PEPT1-mediated prodrug strategy for oral delivery of peramivir , 2018, Asian journal of pharmaceutical sciences.

[33]  E. Shishatskaya,et al.  Battle of GLP-1 delivery technologies. , 2018, Advanced drug delivery reviews.

[34]  D. Drucker.  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.

[35]  Kwangmeyung Kim,et al.  Bile acid transporter mediated endocytosis of oral bile acid conjugated nanocomplex. , 2017, Biomaterials.

[36]  W. Herman,et al.  Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes , 2017, Annals of Internal Medicine.

[37]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[38]  Helen X. Gao,et al.  American Diabetes Association Standards of Medical Care in Diabetes 2017 , 2017, Journal of diabetes.

[39]  Kwangmeyung Kim,et al.  End-Site-Specific Conjugation of Enoxaparin and Tetradeoxycholic Acid Using Nonenzymatic Glycosylation for Oral Delivery. , 2016, Journal of medicinal chemistry.

[40]  David J Brayden,et al.  Intestinal permeation enhancers for oral peptide delivery. , 2016, Advanced drug delivery reviews.

[41]  M. Tschöp,et al.  Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. , 2016, Cell metabolism.

[42]  K. Parang,et al.  Design, synthesis, and evaluation of chitosan conjugated GGRGDSK peptides as a cancer cell-targeting molecular transporter. , 2016, International journal of biological macromolecules.

[43]  Y. Niu,et al.  A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus. , 2016, Bioorganic & medicinal chemistry.

[44]  T. Kruse,et al.  Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. , 2015, Journal of medicinal chemistry.

[45]  D. S. Lee,et al.  Absorption Mechanism of a Physical Complex of Monomeric Insulin and Deoxycholyl-l-lysyl-methylester in the Small Intestine. , 2015, Molecular pharmaceutics.

[46]  Seung Woo Chung,et al.  Oligomeric bile acid-mediated oral delivery of low molecular weight heparin. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[47]  M. Deyoung,et al.  GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence , 2012, Diabetes, obesity & metabolism.

[48]  I. Tamai.  Oral drug delivery utilizing intestinal OATP transporters. , 2012, Advanced drug delivery reviews.

[49]  Nian Gong,et al.  Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity , 2011, British journal of pharmacology.

[50]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[51]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[52]  Yong Gan,et al.  Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. , 2018, Biomaterials.

[53]  T. Vilsbøll,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2017, The New England journal of medicine.

[54]  J. Turner,et al.  The intestinal epithelial barrier: a therapeutic target? , 2017, Nature Reviews Gastroenterology &Hepatology.

[55]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[56]  Seung Woo Chung,et al.  Functional transformations of bile acid transporters induced by high-affinity , 2014 .

[57]  J. Holst,et al.  Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[58]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..